Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04211337) compared two treatment groups in people with a specific type of cancer: 193 participants received selpercatinib (Group A) and 98 participants received either cabozantinib or vandetanib (Group B). The trial was primarily measuring how long participants went without their disease getting worse or dying — a timeframe called "progression-free survival." It also looked at a number of secondary measures, including how many participants' tumours shrank or disappeared, how long those responses lasted, and how long participants survived overall. The reported data shows that for the main measure — time without disease worsening — a final number was only reported for Group B (cabozantinib or vandetanib), at 16.76 months; the corresponding figure for Group A (selpercatinib) was listed as "NA," meaning a final result was not available at the time of reporting. For the secondary measures, the proportion of participants whose tumours shrank or disappeared was reported as 69.4% in Group A and 38.8% in Group B. The length of time those responses lasted was reported for Group B at 16.56 months, while Group A's figure was again listed as not available. A measure called "treatment failure-free survival" — essentially how long participants stayed on treatment without their disease worsening or stopping due to intolerability — was reported as 13.93 months for Group B, with Group A's figure not available. The reported data shows that figures for overall survival and a longer-term progression measure (PFS2) were not reported in the submitted results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40617171) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Thyroid Cancer Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are at least 18 years old (or as young as 12 in some locations if local health authorities allow it).
- You have been diagnosed with a type of thyroid cancer called medullary thyroid cancer (MTC) that cannot be removed by surgery and has either spread or is advanced, and you have not previously been treated with a type of drug called a kinase inhibitor for this advanced or spread disease.
- Your cancer has been shown to be growing on scans compared to a previous scan taken within the last 14 months, and you have measurable or identifiable cancer (though if your cancer can only be seen in bone, additional requirements apply — confirm with trial site).
- Your cancer or a blood/DNA sample has tested positive for a specific change in a gene called RET, and enough tumor tissue is available for further testing.
- Your general health and ability to carry out daily activities is rated at a certain level (scored 0, 1, or 2 on a standard medical scale — confirm with trial site).
- Your blood tests show that your blood, liver, kidney, and electrolyte levels are within an acceptable range.
- If you are able to have children, you agree to use a highly effective form of contraception during the trial and for 4 months after your last dose of the study drug.
- You are able to swallow capsules.
Who may not be able to join:
- Your cancer has a known genetic change other than RET (such as RAS, BRAF, or NTRK) that could stop the study drug from working.
- You have cancer that has spread to the brain and is causing symptoms, has spread along the lining of the brain or spinal cord, or you have untreated pressure on your spinal cord.
- You have significant heart problems, have had a heart attack in the last 6 months, have a history of a specific dangerous heart rhythm problem, or your heart's electrical activity (measured by an ECG) shows certain abnormal readings (confirm with trial site for specific values).
- You have an active infection (bacterial, viral, or fungal) or another serious ongoing illness that is not under control.
- You are actively bleeding or are at high risk of serious bleeding.
- You have or have had another type of cancer, unless it was a certain type of skin cancer, a very early-stage cancer, or a cancer that was diagnosed more than 2 years ago and is no longer active (people with a related condition called MEN2-associated pheochromocytoma may still be eligible — confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM, Eli Lilly and Company
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.